Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Kathleen Dungan MD, MPH

Kathleen M. Dungan MD, MPH

Professor of Medicine and Interim Director, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University, Columbus, Ohio

Kathleen Dungan, MD, MPH, is Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the Ohio State University where she serves as Interim Director for the Division.

Dr. Dungan earned her medical degree from the Ohio State University, and completed her residency in Internal Medicine and fellowship in Endocrinology at the University of North Carolina. She then completed her Masters in Public Health at The Ohio State University. She regularly appears on the "Best Doctors" list. She has served as primary investigator for NIH and other externally sponsored clinical research in glycemic management of hospitalized patients. She has served as lead investigator, steering committee, or national lead for a number of multi-center clinical trials involving diabetes therapeutics and monitoring. She serves as Associate Editor for Endotext and has served on planning committees for the American Diabetes Association Scientific Sessions and the Endocrine Society Clinical Endocrine Update, as well as other editorial board and continuing education planning activities. She has served on advisory panels, clinical trial steering committees, and has published widely on inpatient and outpatient diabetes therapeutics and monitoring.


Dr. Dungan reports the following disclosures:

Consulting fees from Eli Lilly, Dexcom, Insulet

Institutional research fees from Dexcom, Viacyte, Abbott, and Insulet,

Presentation honoraria from Academy for Continued Healthcare Learning, Med Learning Group  

Royalties:  Uptodate.